Top Page
Elixinol Wellness
(Sydney:EXL)
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
Elixinol Wellness Business Overview & Revenue Model
Elixinol Wellness Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.85M | 14.96M | 8.27M | 7.05M | 9.34M | 15.01M |
| Gross Profit | 5.59M | 5.36M | -1.80M | -3.27M | -6.25M | -9.58M |
| EBITDA | -5.00M | -4.01M | -6.81M | -9.28M | -15.51M | -95.94M |
| Net Income | -2.06M | -1.72M | -7.51M | -10.57M | -17.02M | -104.51M |
Balance Sheet | ||||||
| Total Assets | 16.58M | 18.45M | 11.71M | 13.48M | 25.33M | 42.47M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 1.08M | 708.00K | 2.86M | 12.65M | 27.74M |
| Total Debt | 3.10M | 1.94M | 1.26M | 1.83M | 2.71M | 2.74M |
| Total Liabilities | 9.61M | 8.42M | 5.25M | 4.33M | 6.25M | 6.82M |
| Stockholders Equity | 6.96M | 10.03M | 6.46M | 9.16M | 19.08M | 35.65M |
Cash Flow | ||||||
| Free Cash Flow | -2.73M | -3.53M | -2.77M | -8.16M | -14.36M | -22.95M |
| Operating Cash Flow | -2.71M | -3.47M | -2.76M | -8.15M | -14.07M | -22.62M |
| Investing Cash Flow | -516.00K | -66.00K | -1.04M | -869.00K | 172.00K | 2.55M |
| Financing Cash Flow | 2.76M | 3.92M | 1.61M | -757.00K | -1.16M | 27.55M |
Elixinol Wellness Technical Analysis
Elixinol Wellness Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$4.14M | -1.09 | -26.84% | ― | 36.60% | 85.28% | |
44 Neutral | ― | ― | ― | ― | -3.82% | 79.24% | |
41 Neutral | AU$19.03M | -1.28 | ― | ― | -47.30% | 82.53% | |
40 Underperform | AU$12.44M | -0.26 | -401.36% | ― | -26.49% | 61.72% | |
39 Underperform | AU$4.26M | 16.00 | ― | ― | 69.59% | ― | |
37 Underperform | AU$7.21M | -1.45 | ― | ― | -15.81% | -358.33% |
Elixinol Wellness Corporate Events
Elixinol Wellness has announced the resignation of David Fenlon as Chair of the Board, with Gavin Evans stepping in as the new Independent Non-Executive Chair. Evans, who has a strong background in building profitable wellness businesses, has been a strategic adviser to Elixinol and is expected to drive the company’s transformation agenda towards profitability. His leadership is anticipated to enhance operational discipline and growth, benefiting stakeholders and supporting the company’s strategic goals.
Elixinol Wellness Limited announced the cessation of 190,973 securities due to the expiry of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.
Elixinol Wellness Limited has announced the quotation of 136,996,310 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with its securities.
Elixinol Wellness Ltd held a General Meeting where shareholders approved several resolutions, including the ratification of prior issue of Tranche 1 Placement Shares and the approval to issue Tranche 2 Placement Shares. These approvals are expected to support the company’s capital structure and facilitate further growth opportunities, enhancing its market position and potentially benefiting stakeholders.
Elixinol Wellness Ltd has announced a reminder for its shareholders about an upcoming extraordinary general meeting scheduled for 10 November 2025. The meeting, initially set for 31 October 2025, has been rescheduled, and shareholders have been provided with an amended Notice of Meeting, Access Letter, and Proxy Form. Proxy voting will close on 8 November 2025, but shareholders can still vote by attending the meeting directly. This meeting is crucial for stakeholders as it provides an opportunity to engage with the company’s strategic direction and decisions.
Elixinol Wellness reported a Q3 revenue of $3.8 million, maintaining its previous year’s performance due to strategic portfolio rationalization. The company achieved a 300 basis point increase in gross margin, driven by e-commerce and core brands, and is implementing cost-reduction measures to enhance operational efficiency. A capital raise of $2.5 million is supporting growth and margin initiatives, with Hemp Foods Australia experiencing its strongest quarter and The Healthy Chef anticipating a rebound in Q4.
Elixinol Wellness Limited has issued a prospectus for the offer of new options to select investors, including up to 1 new option for every new share issued to invited placement investors and 35,000,000 new options to the lead manager for capital raising and advisory services. The offers are not open to the general public, and applications can only be made by invited investors. This move is part of Elixinol’s strategy to raise capital and enhance its market positioning, although the investment is considered speculative and involves risks.
Elixinol Wellness Ltd has postponed its Extraordinary General Meeting originally scheduled for 31 October 2025 to 11 November 2025 due to an administrative error by the share registrar, which failed to notify certain shareholders within the statutory timeframes. The company is committed to ensuring all shareholders have a fair opportunity to participate and vote, and will issue a new Notice of Meeting and related documents. This postponement underscores Elixinol’s dedication to transparency and shareholder engagement, despite the inconvenience caused.
Elixinol Wellness Limited announced the cancellation of a previous securities issuance announcement due to the expiration of the offer period associated with a cleansing prospectus. This decision reflects the company’s adherence to regulatory requirements and impacts its operational plans regarding the proposed non-pro rata offer of securities.
Elixinol Wellness Limited has announced an Extraordinary General Meeting to be held virtually on October 31, 2025. This meeting will allow shareholders to discuss and vote on company matters, with proxy voting available online. The company emphasizes its commitment to environmental sustainability by offering digital access to meeting documents.
Elixinol Wellness Limited announced an update to a previous securities issue announcement, detailing the issuance of 35 million options to the lead manager as part of a fee arrangement. This issuance is contingent upon shareholder approval and a minimum placement raising of AUD1.5 million, with the options exercisable at 2 cents and expiring on October 23, 2027. This move aims to enhance the company’s financial strategy and potentially strengthen its market position.
Elixinol Wellness Limited, listed on the ASX under the code EXL, has announced a prospectus for an offer of up to 100,000 new shares at $0.10 each, aiming to raise up to $10,000. The prospectus is designed to remove trading restrictions on the sale of shares issued under this offer and previous ones. The company emphasizes that the investment should be considered speculative, with no guarantees on returns or dividends, and advises potential investors to seek professional advice.
Elixinol Wellness Limited has announced the quotation of 46,800,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 12, 2025. This move is part of a previously announced transaction, potentially impacting the company’s market presence and providing stakeholders with increased liquidity and investment opportunities.
Elixinol Wellness Limited announced a proposed issue of securities, including options and ordinary fully paid shares, set to be issued on October 24, 2025. This move is part of the company’s strategy to raise capital, potentially impacting its market position and providing opportunities for stakeholders to engage with its growth initiatives.
Elixinol Wellness Limited has announced a proposed issue of 46,800,000 ordinary fully paid securities, with the issue date set for September 12, 2025. This move is part of the company’s strategic efforts to enhance its market position and potentially raise capital for future growth initiatives, impacting its operational capabilities and stakeholder interests.
Elixinol Wellness Ltd has successfully raised $2.5 million through a well-supported two-tranche placement, exceeding its initial target of $2 million. The funds will be used to enhance working capital, support inventory growth, streamline operations, and shift towards higher-margin channels to achieve sustained profitability. The company has also appointed Gavin Evans as a strategic advisor to aid in its transformation, following recent acquisitions. This move reflects strong investor confidence in Elixinol’s brands and strategic direction, positioning the company for profitable growth.